Advertisement
RVTY vs TMO
Which Stock Would AI Choose? Revvity (RVTY) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- RVTY (Revvity) is a mid-cap life sciences and diagnostics company showing stronger recent price momentum, while TMO (Thermo Fisher Scientific) is a diversified, large-cap "picks and shovels" supplier to science with far greater scale.
- Revvity's Diagnostics segment is driving growth (pro forma organic revenue up 11% in its latest quarter), while its Life Sciences unit has been softer due to software and contract-renewal timing.
- Thermo Fisher is benefiting from a broad recovery in pharma and biotech funding and has raised its full-year guidance after a recent earnings beat.
- Revvity has been re-rating rapidly (up roughly 75% over the past year), which has pushed its valuation above the average analyst price target; Thermo Fisher trades near its consensus target.
- Both companies are positioning around AI-enabled workflows and laboratory software as a growth catalyst, but Thermo Fisher's diversified model offers a different risk profile than Revvity's more concentrated exposure.
Introduction
Revvity and Thermo Fisher Scientific both serve the life sciences and diagnostics end markets, yet they operate at very different scales and with distinct business mixes. This stock comparison is relevant for traders and investors evaluating relative performance, market positioning, and momentum within the healthcare and laboratory tools sector. Because both names are sensitive to the same underlying drivers—pharmaceutical and biotech research spending, diagnostic testing volumes, and adoption of AI-enabled laboratory software—comparing them helps clarify which type of exposure, growth profile, and valuation better suits a given portfolio objective in the current market environment.
RVTY Overview and Recent Performance
Revvity, Inc. (RVTY) is a health sciences company providing technologies and services across discovery-to-cure workflows, including translational multi-omics, biomarker identification, imaging, screening, diagnostics, and informatics. With roughly $2.9 billion in 2025 revenue and about 11,000 employees, it is a constituent of the S&P 500.
In recent weeks, Revvity's stock has exhibited strong relative performance, gaining roughly 75% over the past year and advancing markedly on a three-month and year-to-date basis. This momentum reflects a rapid re-rating as investors reassess its exposure to AI-enabled software, notably its Signals platform and related large language model (LLM) integrations, as well as its diagnostics franchise. Its most recent quarterly results beat expectations, driven by Diagnostics strength, while Life Sciences revenue declined modestly on software timing. Management also raised full-year guidance and announced a definitive agreement to divest its China Immunodiagnostics business. Notably, the stock now trades above its average analyst price target, suggesting much of the optimism is already reflected in the valuation.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. (TMO) is the world's largest company serving science, with annual revenue exceeding $45 billion. Its portfolio spans life sciences research tools, analytical instruments, specialty diagnostics, laboratory products, and biopharma services through brands including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Patheon, and PPD.
Thermo Fisher has also strengthened in recent market activity, with a roughly 26% return over the past three months and a one-year total shareholder return in the mid-20% range. Its recent earnings beat was supported by improving pharma and biotech funding—a segment representing about 60% of revenue—alongside new clinical research contract wins and product launches. The company raised its full-year adjusted earnings per share (EPS) and revenue guidance and is divesting its microbiology business to sharpen its portfolio mix. Analyst sentiment is broadly constructive, with a consensus "Strong Buy" rating, though the stock trades near its average price target, leaving limited consensus upside from current levels.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers across varied timeframes, strategies, and risk profiles. Because not every bot suits every market regime, Tickeron curates only the strongest performers into its Trending AI Robots section. These selected bots differ in trading style, holding period, statistical profile, and the set of tickers they monitor, with many featuring detailed performance statistics and track records designed to help traders evaluate suitability. The page is refreshed to reflect current conditions, so the featured bots represent those best aligned with prevailing market dynamics. Traders and investors interested in a data-driven, automated approach can explore the Trending AI Robots page to review the available bots and their current statistics.
Head-to-Head Comparison
The most fundamental contrast between these two names is scale and diversification. Thermo Fisher's multi-segment, $45 billion-plus revenue base provides breadth across research, diagnostics, and biopharma services, whereas Revvity is a more focused, mid-cap operator concentrated in diagnostics, reagents, instruments, and software. This concentration cuts both ways: it gives Revvity sharper exposure to high-growth themes like AI-enabled informatics, but it also makes its results more sensitive to segment-specific swings such as software renewal timing.
On momentum, Revvity has been the stronger performer over the past year, but that strength has pushed its valuation to a premium relative to consensus targets. Thermo Fisher's gains have been steadier and are backed by improving end-market funding rather than a single catalyst, which some investors may view as more durable. Risk profiles also differ: Revvity carries ongoing China and portfolio-transition considerations, while Thermo Fisher faces execution risk around its divestitures and the possibility that life science tools valuations already price in a full recovery.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative positioning, and catalyst quality, Tickeron's AI would likely tilt its preference toward Thermo Fisher Scientific (TMO) in the current environment. Revvity's momentum is compelling, but its rapid re-rating and above-consensus valuation introduce a higher probability of consolidation. Thermo Fisher's steadier uptrend, diversified revenue base, and improving fundamentals offer a comparatively more balanced risk-reward profile. This is a probabilistic assessment of trend and positioning rather than a definitive forecast, and relative attractiveness may shift as market conditions evolve.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RVTY is a Hold and TMO is a StrongBuy.
RVTY's RSI Indicator leaves overbought zone
The 10-day RSI Oscillator for RVTY moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In 24 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at 77%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 68 cases where RVTY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Moving Average Convergence Divergence Histogram (MACD) for RVTY turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 33 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
RVTY broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on RVTY as a result. In 61 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where RVTY advanced for three days, in 200 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 122 of 181 cases where RVTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. RVTY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.424) is normal, around the industry mean (65.876). P/E Ratio (75.481) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (0.734) is also within normal values, averaging (3.473). Dividend Yield (0.002) settles around the average of (0.002) among similar stocks. P/S Ratio (5.656) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVTY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Momentum Indicator for TMO turns positive, indicating new upward trend
TMO saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 58 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 192 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 133 of 244 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 17 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 47%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 67 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 24 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.892) is normal, around the industry mean (65.876). P/E Ratio (37.453) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
RVTY | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 70 | |
SMR RATING 1..100 | 86 | 60 | |
PRICE GROWTH RATING 1..100 | 3 | 14 | |
P/E GROWTH RATING 1..100 | 8 | 25 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (65) in the Medical Specialties industry is in the same range as RVTY (79). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
TMO's Profit vs Risk Rating (70) in the Medical Specialties industry is in the same range as RVTY (100). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is in the same range as RVTY (86). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's Price Growth Rating (3) in the Medical Specialties industry is in the same range as TMO (14). This means that RVTY’s stock grew similarly to TMO’s over the last 12 months.
RVTY's P/E Growth Rating (8) in the Medical Specialties industry is in the same range as TMO (25). This means that RVTY’s stock grew similarly to TMO’s over the last 12 months.
| RVTY | TMO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 47% |
| Stochastic ODDS (%) | 1 day ago 71% | 1 day ago 57% |
| Momentum ODDS (%) | 1 day ago 69% | 1 day ago 67% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 56% |
| TrendWeek ODDS (%) | 1 day ago 66% | 1 day ago 61% |
| TrendMonth ODDS (%) | 1 day ago 66% | 1 day ago 63% |
| Advances ODDS (%) | 5 days ago 67% | 5 days ago 62% |
| Declines ODDS (%) | 1 day ago 67% | 1 day ago 61% |
| BollingerBands ODDS (%) | 1 day ago 69% | 1 day ago 47% |
| Aroon ODDS (%) | 1 day ago 67% | 1 day ago 55% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RVTY’s FA Score shows that 2 FA rating(s) are green while TMO’s FA Score has 2 green FA rating(s).
- RVTY’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RVTY’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
- RVTY’s TA Score: 3 bullish, 5 bearish.
- TMO’s TA Score: 3 bullish, 5 bearish.
Price Growth
RVTY (@Medical Specialties) experienced а -5.48% price change this week, while TMO (@Medical Specialties) price change was -0.33% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.28%. For the same industry, the average monthly price growth was -6.26%, and the average quarterly price growth was +40.23%.
Reported Earning Dates
RVTY is expected to report earnings on Nov 03, 2026.
TMO is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Medical Specialties (-1.28% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement